Back to results
US 12,012,635 B2Granted
Methods and compositions for assessing patients with preeclampsia-related conditions using MicroRNA
AssigneeEwinger, Inc.
InventorsEdward E. Winger, Jane Reed
Life of this patent
Estimating the term…
Abstract
The invention is directed to methods and compositions for collecting a non-placental biological samples of cells and quantifying and comparing levels of expression of microRNAs to characterize a preeclampsia-related condition. The samples may be collected before or after an intervention or may be collected over a period of time. One of the samples may be a control sample. Patients may then be treated according to their response.
Claims8
A method comprising:
- (a) quantifying the expression of one or more microRNAs (miRNAs) in one or more maternal blood cells of a pregnant human being, the one or more miRNAs being selected from the group consisting of hsa-miR-7-5p, hsa-miR-16, hsa-miR-199-5p, hsa-miR-575, and hsa-miR-582-5p;
- (b) comparing the expression of the one or more miRNAs quantified in step a) to the expression of the same one or more miRNAs in a control sample to determine whether the pregnant human being is at risk of developing a preterm birth, wherein an increase in the expression of the one or more miRNAs in the pregnant human being relative to the control sample indicates the pregnant human being is at risk of developing a preterm birth;
- and,
- (c) treating a pregnant human being identified in step b) as being at risk of developing a preterm birth using immunotherapy.
1 more element
A method comprising:
- (a) quantifying the expression of one or more microRNAs (miRNAs) in one or more maternal blood cells of a pregnant human being, the one or more miRNAs being selected from the group consisting of hsa-miR-7-5p, hsa-miR-16, hsa-miR-199-5p, hsa-miR-575, and hsa-miR-582-5p;
- (b) comparing the expression of the one or more miRNAs determined in step a) to the expression of the one or more miRNAs in a control sample to determine whether the pregnant human being is at risk of preeclampsia and/or related condition(s), wherein an increase in expression of the one or more miRNAs in the pregnant human being relative to the control sample indicates the pregnant human being is at risk of preeclampsia and/or related condition(s) selected from the group consisting of premature rupture of membranes (PROM), intrauterine growth retardation (IUGR), gestational diabetes, proteinuria, hypertension, edema, HELLP Syndrome, eclampsia, low birth weight, miscarriage, pregnancy-induced hypertension, Metabolic Syndrome associated with heart disease, pregnancy bleeding, placental abruption, placenta accreta, placental hemorrhage, placental infarction, preterm labor, preterm birth, stillbirth, excess or low amniotic fluid, subchorionic hemorrhage, recurrent pregnancy loss and anti-phospholipid antibody syndrome, thrombophilia, fetal thrombotic vasculopathy, villitis of unknown etiology, poor endometrial lining development, and infertility;
- and,
- (c) treating a pregnant human being identified in step b) as being at risk using immunotherapy.
1 more element
Dependencies are inferred from the claim text.